Results

Bristol-Myers Squibb Company

10/01/2021 | Press release | Distributed by Public on 10/01/2021 05:00

European Medicines Agency Validates Bristol Myers Squibb’s Application for Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy